

NovAliX Conference 2013

Biophysics in Drug Discovery

Confirmed Speakers

Confirmed Speakers

KN01 - Biophysical Methods and Fragment Based Drug Discovery: Targeting Protein-Protein Interactions in Cell Regulatory Systems



Prof. Sir Tom BLUNDELL
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

PL04 - Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics: DOT1L and EPZ-5676

Dr Ann BORIACK-SJODIN
(EPIZYME, Cambridge, United States)

PL08 - Backscattering Interferometry: An Enabling Drug Development Technology



Dr Darryl BORNHOP
(VANDERBILT UNIVERSITY, Nashville, United States)

KN03 - Combining X-Ray Crystallography and Single-Molecule Methods to Probe Antibiotic Inhibition of Translation



Prof. Jamie CATE
(UNIVERSITY OF CALIFORNIA, Berkeley, United States)

PL02 - Enabling GPCR Drug Discovery Through Structural and Biophysical Insights



Dr Rob COOKE
(HEPTARES, Hertfordshire, United Kingdom)

PL10 - Application of SPR Biosensors Throughout the Drug Discovery Process



Prof. Helena DANIELSON
(UPPSALA UNIVERSITY, Uppsala, Sweden)

PL07 - Label-Free, Immobilisation-Free Interaction Studies Using Microscale Thermophoresis



Dr Stefan DUHR
(NANOTEMPER, Munich, Germany)

PL03 - Biophysics to Drive Lead Discovery



Dr Matthias FRECH
(MERCK, Darmstadt, Germany)

PL01 - Binding of Drug Substances to Molecular Targets Investigated by Biophysical Methods



Dr Michael HENNIG
(F. HOFFMANN-LA ROCHE LTD., Villigen, Switzerland)

NovAliX Conference 2013

Biophysics in Drug Discovery

Confirmed Speakers

PL06 - Can we Use Kinetics and Thermodynamics to Guide Drug Discovery?



Dr Geoff HOLDGATE
(ASTRAZENECA, Macclesfield, United Kingdom)

PL09 - Towards Personalised Cancer Medicine with New NMR Tools to Probe Small GTPase Proteins



Dr Chris MARSHALL
(UNIVERSITY OF TORONTO, Toronto, Canada)

PL11 - Finding Active Ligands to kRAS Using Solution State NMR



Dr Till MAURER
(GENENTECH, South San Francisco, United States)

PL12 - Biophysics in Pharmaceutical Lead Discovery



Dr Johannes OTTL
(NOVARTIS INSTITUTE OF BIOMEDICAL RESEARCH, Basel, Switzerland)

KN02 - Molecular Mechanism of Action (MMOA) in Drug Discovery



Dr David SWINNEY
(IRND3, Mountain View, United States)

PL05 - Investing in Knowledge: Combining Biophysical Data in Fragment-Based Drug Discovery



Dr Glyn WILLIAMS
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

Oral Communications

OC09 - Identification and Validation of Small Molecule Inhibitors of G Protein Beta 1 Gamma 2

Dr Preeti BAKRANIA
(MRC TECHNOLOGY, London, United Kingdom)

OC01 - Biophysical Investigations of the Synergistic Activities of Antimicrobial Peptides: New Strategies to Fight Multiresistance

Prof. Burkhard BECHINGER
(UNIVERSITY OF STRASBOURG, Strasbourg, France)

OC05 - Bringing Light into Antibody Binding Characteristics in Crude Extracts by Means of FCCS



Dr Frank BECKER
(INTANA BIOSCIENCE GMBH, Planegg, Germany)

OC04 - Pharmacokinetics and the Drug-Target Residence Time Concept

NovAliX Conference 2013

Biophysics in Drug Discovery

Confirmed Speakers



Dr Göran DAHL
(ASTRAZENECA, Mölndal, Sweden)

OC02 - X-Ray Crystallography, Kinetic Target-Guided Synthesis and NMR to Unravel the Mode of Action of Insulin Degrading Enzyme Modulators



Prof. Rebecca DEPRez-POULAIN
(UNIVERSITY OF LILLE, Lille, France)

OC07 - Binding Rate Constants Measured on Microliter Volume Using On-Chip Temperature Modulation and Fluorescence Lock-In Detection

Dr Charlie GOSSE
(CNRS, Marcoussis, France)

OC03 - Residence and Recognition Time and their Use for Structure Kinetic Relationships and for Judging Efficacy of Lead Series

Dr Markku HÄMÄLÄINEN
(GE HEALTHCARE BIO-SCIENCES, Uppsala, Sweden)

OC10 - Fragments at UCB: Implementation of Non-Covalent Mass Spectrometry and ¹⁹F NMR as Orthogonal Screening Techniques

Dr Hannah MAPLE
(UCB, Slough, United Kingdom)

OC06 - Detection and Analysis of Proteins with an Electro-Switchable DNA Chip

Dr Ralf STRASSER
(DYNAMIC BIOSENSORS GMBH, Martinsried, Germany)

OC08 - CRYO-TEM: The Way to Answer Real Biological Questions through Unraveling the 3D Mechanistics of Protein

Dr Thomas WOHLFARTH
(FEI, Eindhoven/Acht, The Netherlands)